Results 41 to 50 of about 4,608 (197)

Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle. [PDF]

PLoS ONE, 2015
The aim of the present study was to investigate long term effects of motor denervation by botulinum toxin complex type A (BoNT/A) from Clostridium Botulinum, on the afferent fibers originating from the gastrocnemius muscle of rats.
Guillaume Caron, Tanguy Marqueste, Patrick Decherchi   +2 more
doaj   +1 more source

Wound Botulism Caused by Botulinum Neurotoxin Type A in a Chronic Parenteral Drug Abuser

Case Reports in Neurology, 2020
Botulism is an acute paralytic disease caused by botulinum neurotoxin (BoNT)-mediated inhibition of neurosignaling at the neuromuscular junction. BoNTs are produced by gram positive, anaerobic, spore-forming bacteria from the genus Clostridium,most ...
Sohun Awsare, David Chirikian, Forshing Lui   +2 more
doaj   +1 more source

Botulinum toxin-A for the treatment of overactive bladder: UK contributions

, 2013
Background: Botulinum toxin-A (BoNT/A) is now established second-line management for refractory overactivebladder (OAB) and recognised in many incontinence guidelines and pathways.
Fowler, CJ, Panicker, J. N., Fowler, C. J., Dowson, C, Khan, MS, Seth, JH, Dasgupta, P, Dasgupta, P., Panicker, JN, Sahai, A, Dowson, C., Seth, J. H., Khan, M. S., Sahai, Arun   +13 more
core   +1 more source

Recombinant botulinum toxin as a new stage in the development of botulinum toxin therapy. Possibilities and perspectives of use in neurological practice

Неврология, нейропсихиатрия, психосоматика, 2022
Currently, eight natural serotypes of botulinum neurotoxin (BNT-A-G, -X) are known. The mechanism of action of all BNT serotypes is presynaptic blockade of SNARE transport proteins (Soluble N-ethylmaleimide-sensitive factor [NSF] Attachment Protein ...
R. K. Shikhkerimov, E. V. Istomina
doaj   +1 more source

A case of acute pulmonary complication due to botulinum toxin: Patient with central pontine myelinolysis developed acute respiratory distress syndrome after botulinum neurotoxin type A injection into spastic lower extremity muscles

, 2023
Chemodenervation with botulinum neurotoxin type A (BoNTA) is the preferred method for focal spasticity management among various treatment options. While BoNTA injection is considered safe, its widespread use and increasing evidence raise safety concerns.
Hasan Hüseyin Gökpınar, Furkan Ertürk Urfalı, Urfalı, Furkan Ertürk, Gökpınar, Hasan Hüseyin   +3 more
core   +1 more source

Novel approaches to the treatment of cervical dystonia. The concept of dual navigation control

Неврология, нейропсихиатрия, психосоматика, 2021
Сervical dystonia (CD) is the most common type of focal dystonia (up to 50% of all dystonia cases). Botulinum neurotoxin (BoNT) injections is the treatment choice for CD.
A. P. Kovalenko, Z. A. Zalyalova, A. F. Ivolgin   +2 more
doaj   +1 more source

The Spectrum of Abnormal Tongue Movements: Review of Phenomenology, Etiology, and Differential Diagnosis

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan, Seyed‐Mohammad Fereshtehnejad, Christos Ganos, Emily Swinkin, Anthony E. Lang   +4 more
wiley   +1 more source

Anatomical Injection Guidelines for Glabellar Frown Lines Based on Ultrasonographic Evaluation

Toxins, 2021
When botulinum neurotoxin (BoNT) is injected to treat glabellar frown lines, the corrugator supercilia muscle (CSM) and procerus muscles are the main targets.
Soo-Bin Kim, Hyoung-Moon Kim, Haeryun Ahn, You-Jin Choi, Kyung-Seok Hu, Wook Oh, Hee-Jin Kim   +6 more
doaj   +1 more source

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real‐World Early Experience Program

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom‐engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relief in Phase 3 trials. Objective To report findings from PrevU, an early experience, real‐world observational
Laxman Bahroo, Aaron Ellenbogen, Robert A. Hauser, Han S. Lee, Peter McAllister, Atul T. Patel, Rashid Kazerooni, Todd M. Gross, Julia Sparrow, Conor J. Gallagher, David A. Hollander   +10 more
wiley   +1 more source

The Effect of Different Doses of Botulinum Toxin on Masseter Muscle in Patients with Bruxism.

Erbil Dental Journal, 2022
Background and Objectives: Botulinum toxin type A is produced by clostridium botulinum. It acts by inhibiting the release of acetylcholine from cholinergic neurons.
Kawa F. Dizaye, Sarezh Jamal Jalal
doaj